NCT05985655 - Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

May 31, 2028

Conditions

Advanced Solid TumorHead and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)Breast CarcinomaHigh-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma

Interventions

DRUG

GTAEXS617

Administered as specified in the treatment arm.

DRUG

SoC

Participants will receive either fulvestrant (breast cancers) or paclitaxel + bevacizumab (HGSOC) as specified in the treatment arm.

Trial Locations (12)

49546

RECRUITING

START Midwest, Grand Rapids

78229

RECRUITING

START San Antonio, San Antonio

84119

RECRUITING

START Mountain Region, West Valley City

Unknown

RECRUITING

GZA Ziekenhuizen - Campus Sint-Augustinus, Antwerp

RECRUITING

Clinique Universitaires Saint-Luc, Brussels

RECRUITING

Institute Jules Bordet, Brussels

RECRUITING

CHU Sart Tilman, Liège

RECRUITING

The Beatson West of Scotland Cancer Centre, Glasgow

RECRUITING

UCL Hospitals NHS Foundation Trust, London

RECRUITING

The Christie NHS Foundation Trust, Manchester

RECRUITING

Newcastle Upon Tyne NHS Foundation Trust, Newcastle upon Tyne

RECRUITING

Oxford University Hospitals NHS Foundation Trust, Oxford

All Listed Sponsors

lead

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

INDUSTRY